DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Sequence (acquired by WeightWatchers) connects members with clinicians prescribing GLP-1 and other weight loss medications.
A credible GLP-1 telehealth program with a strong behavioral backbone
Sequence, rebranded as WeightWatchers Clinic and offered through the Med+ membership, is one of the more established and clinically grounded GLP-1 telehealth services. Its real value is combining brand-name prescriptions with insurance coordination and WeightWatchers' decades-old behavioral and nutrition program. The big catch: membership is relatively cheap, but the medication itself often is not, and coverage is far from guaranteed.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Sequence launched as an independent telehealth platform focused on insurance-covered access to metabolic and weight-loss medications. In March 2023, WW International (WeightWatchers) acquired it for roughly $132 million and has since rebranded the service as WeightWatchers Clinic (you will also see it marketed as the "GLP-1 Program" or "WW Clinic"). The original "Sequence" branding is being retired, so if you are searching for Sequence today, you are looking at WeightWatchers Clinic — the names refer to the same service.
The core idea is a medication-plus-behavior model. Unlike a bare-bones "tele-prescribing" site that simply mails you a drug, this program is built around an ongoing clinical relationship layered on top of WeightWatchers' coaching ecosystem. The typical onboarding flow works like this:
Crucially, the prescribing is done by an affiliated medical group, "WeightWatchers Clinic," not by WeightWatchers' commercial business directly — a standard structure for telehealth that keeps clinical decisions inside a licensed practice.
WeightWatchers Clinic is aimed at adults who qualify medically for weight-loss pharmacotherapy — not people looking for a quick, off-label injection. The clinical thresholds follow standard obesity-medicine criteria: GLP-1 medications for chronic weight management are generally appropriate for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (such as type 2 diabetes, hypertension, or sleep apnea). These mirror the FDA-approved indications for drugs like Wegovy and Zepbound.
A clinician makes the final call, and not everyone who signs up will be prescribed a GLP-1. Some people will be steered toward other medications or declined if a drug is unsafe for them. This gatekeeping is a feature, not a bug — it is part of what separates a legitimate medical program from a pill mill.
The program prescribes only FDA-approved, brand-name medications — an important and recently changed detail. Depending on your medical profile and insurance, a clinician may prescribe:
A significant policy shift happened in 2025: WeightWatchers stopped offering compounded semaglutide to members in May 2025 (it stopped enrolling new members on compounded semaglutide on May 21, 2025, and began transitioning existing members to branded medication shortly after). This followed the FDA declaring the semaglutide shortage resolved in February 2025 and the subsequent wind-down of the compounding allowances that had existed during the shortage — state-licensed pharmacies' authority to compound semaglutide under Section 503A lapsed on April 22, 2025, with registered 503B outsourcing facilities given until May 22, 2025. Many telehealth competitors had built their cheap-injection businesses on compounded versions; WeightWatchers' move to brand-only is more conservative and arguably safer (branded drugs are FDA-inspected and dose-verified), but it also removes the cheapest path to a GLP-1. There is still no FDA-approved generic of semaglutide or tirzepatide — the two drugs most relevant here — so for those medications "brand-only" effectively means full branded pricing unless insurance helps. (Generic liraglutide is now available: the FDA approved a generic of Victoza in December 2024 and a generic of Saxenda in August 2025, but liraglutide is a substantially less effective, daily older-generation GLP-1.)
The program's value depends heavily on the underlying drugs, and the evidence for GLP-1s in obesity is genuinely strong — among the most robust in modern obesity medicine.
Two honest caveats. First, these are averages — individual results vary widely, and a minority of people respond poorly. Second, the weight loss is maintained only as long as you keep taking the drug: extension data (e.g., STEP-1 follow-up) show that most lost weight returns after stopping. This is exactly why a coaching-plus-medication model can matter, though even with coaching, discontinuation usually means regain.
GLP-1 medications are well-studied but not benign. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — which are usually worst during dose escalation and tend to ease over time (per FDA labeling for Wegovy and Zepbound). More serious but less common concerns include gallbladder problems, pancreatitis, and, in people with diabetes on insulin or sulfonylureas, hypoglycemia.
These drugs carry a boxed warning for a risk of thyroid C-cell tumors seen in rodent studies; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA labeling). They should not be used in pregnancy. This is precisely where a real clinical program adds value: a proper intake, lab work, and a licensed prescriber are supposed to screen for these contraindications before you ever inject anything.
This is where prospective members most often get confused, because the membership fee and the medication are billed separately.
Membership. WeightWatchers Clinic is sold on a 12-month commitment. As of mid-2026, the advertised pricing is a promotional $25/month for the first three months, then $74/month for the remainder of the 12-month term (the company also markets other commitment tiers, so the exact intro rate can vary). The plan auto-renews for another 12 months at the standard monthly rate unless you cancel. This membership covers the clinical access, coaching, dietitian support, insurance navigation, and the WeightWatchers app — but not the drug itself. The membership fee is not reimbursable by insurance.
Medication. The GLP-1 is a separate cost, and it is the big variable:
So the realistic "all-in" monthly cost ranges from roughly the membership fee alone (if your insurance fully covers the drug) up to several hundred or even four figures per month if you are paying cash for a branded medication. Anyone evaluating this program should treat the $74/month as the floor, not the ceiling, and use the company's cost estimator and their own insurance benefits to model the true number.
On legitimacy, WeightWatchers Clinic scores well relative to the broader GLP-1 telehealth field. It uses board-certified obesity/weight-medicine clinicians, requires lab work and a video visit before prescribing, prescribes only FDA-approved branded drugs, and is backed by a decades-old, name-brand company rather than an anonymous startup. The decision to drop compounded semaglutide once the legal basis for it expired is a point in its favor on safety, even though it raised costs.
Two pieces of context every prospective member should know:
Pros:
Cons:
The GLP-1 telehealth market splits roughly into two camps. Compounding-first players (and the cheaper tiers at companies like Hims & Hers, Ro, and various direct-to-consumer clinics) have competed largely on low monthly prices for compounded semaglutide or tirzepatide — attractive on cost, but with the regulatory and quality questions that come with compounded drugs, especially now that the shortage-era compounding allowances have lapsed. Brand-and-behavior players like WeightWatchers Clinic and Noom Med emphasize FDA-approved drugs plus coaching.
WeightWatchers Clinic's clearest differentiator is its behavioral infrastructure — decades of coaching methodology, dietitian access, and a mature tracking app — which directly targets the weakest point of drug-only weight loss: keeping the weight off. Its clearest disadvantage is price flexibility: if you simply want the cheapest possible GLP-1 and do not value the coaching wrapper, a compounding-focused competitor will usually be cheaper, and a month-to-month service will be less of a commitment. If you want a structured, medically supervised program from a recognizable brand and you have (or can get) insurance coverage, WeightWatchers Clinic is competitive.
Sequence — now WeightWatchers Clinic — is one of the more legitimate, clinically grounded options in GLP-1 telehealth. It does the things a responsible program should: real clinicians, lab work, FDA-approved branded medications, dose management, and a serious behavioral-support layer that addresses the hardest part of weight loss, maintenance. The underlying drugs (semaglutide, tirzepatide) have excellent trial evidence for substantial weight loss.
The honest reservations are about money and commitment, not medicine. The membership fee is separate from the medication, the move to brand-only drugs eliminated the cheap path, and the 12-month auto-renewing term is inflexible. The parent company also just emerged from bankruptcy. For someone who values structure, coaching, and a name-brand program — and especially someone whose insurance will cover the drug — it is a reasonable and relatively safe choice. For someone whose only goal is the lowest possible price on a GLP-1, a leaner competitor may fit better. As with every weight-loss medication, the central caveat applies: this is a long-term, likely indefinite commitment, because stopping the drug usually means regaining the weight.
Sequence is a telehealth platform, not a drug. You complete an online health-history questionnaire, then have a video visit with a board-certified clinician who decides whether a prescription weight-loss medication is safe and appropriate for you. The medications prescribed are mostly GLP-1 (and dual GLP-1/GIP) receptor agonists such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda); non-GLP-1 options like metformin or naltrexone/bupropion may also be used when appropriate. These drugs mimic gut hormones that slow stomach emptying, blunt appetite, and increase fullness, so many people eat less without constant hunger. Layered on top is WeightWatchers' behavioral program: the Points food system, dietitian access, fitness guidance, and a GLP-1 Success Program focused on protein intake and muscle preservation during weight loss.
Active ingredient: Brand-name GLP-1
Real-world and trial evidence for these medications is genuinely strong, though the platform-specific figures should be read with caution. A 2024 retrospective analysis in the journal Obesity (Ard et al.) of the WeightWatchers/Sequence telehealth program reported that, among patients with complete data at 12 months, average weight loss was about 19.4% of initial body weight, with roughly 21.2% on tirzepatide and the semaglutide formulations (Wegovy and Ozempic) in the mid-teens, broadly 13 to 15 percent. A key caveat: of the 53,590 patients who started treatment, only about 6,089 had complete 12-month data, so these completer averages likely overstate typical results because people who stopped early or regained are underrepresented. These outcomes are broadly in line with the pivotal drug trials: semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks in STEP 1 (NEJM 2021); tirzepatide produced roughly 20.9% (15 mg, treatment-regimen estimand) and up to about 22.5% over 72 weeks in SURMOUNT-1 (NEJM 2022); and in the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide outperformed semaglutide, about 20.2% versus 13.7% at 72 weeks. Individual results vary widely and depend heavily on staying on the medication and engaging with the program.
A realistic timeline of what Sequence by WeightWatchers users typically experience. Individual results vary; this is educational, not medical advice.
You complete an online health-history quiz, then have a video visit with a board-certified clinician who reviews your history and decides whether a GLP-1 (e.g., semaglutide or tirzepatide) or other medication is appropriate. If prescribed, your care team begins working with your insurance on coverage and prior authorizations; there is no instant approval, and not everyone qualifies.
After insurance/pharmacy steps clear, medication is delivered to your door or a chosen pharmacy and you start the lowest dose (semaglutide 0.25 mg or tirzepatide 2.5 mg weekly) — a starter dose meant to limit side effects, not to drive weight loss. Mild nausea, fullness, or constipation often appear in these first weeks, typically strongest in the 1-2 days after an injection and easing over the following days.
The clinician steps the dose up roughly every 4 weeks (for example semaglutide 0.25 to 0.5 mg, tirzepatide 2.5 to 5 mg) with monthly check-ins, and a dietitian/coach supports food and activity habits. Reduced appetite usually becomes more noticeable as the dose rises, and many people see early weight loss begin — but a brief return of nausea is common after each increase and the schedule may be slowed if side effects are bothersome.
Most people reach a maintenance or near-maintenance dose during this window and weight loss tends to be steadiest here, paired with ongoing monthly clinician visits and habit coaching. Real-world and trial data commonly show roughly low-double-digit percent body-weight loss by around 6 months, though individual results vary widely and some people lose less or tolerate the medication poorly.
Pivotal trials measured results at 68-72 weeks: about 15% average body-weight loss on semaglutide 2.4 mg (STEP 1) and about 21% on tirzepatide 15 mg (SURMOUNT-1), and WeightWatchers cites an average near 21% at 12 months for members on a GLP-1. These are averages from supervised programs with diet and activity, not guarantees, and weight loss typically slows and plateaus as you approach your body's new set point.
GLP-1 treatment is generally long-term: stopping the medication often leads to regaining a meaningful portion of lost weight, so the program continues with at least monthly clinician oversight, refills, and behavior support. Your clinician may adjust the dose for tolerability or maintenance, and decisions to pause or stop should be made with them rather than on your own.
The most common side effects come from the medications, not the platform, and are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst when starting or increasing the dose and often easing over time. Slow dose titration and dietary adjustments can help. Less common but serious risks include an FDA boxed warning for thyroid C-cell tumors (based on rodent studies; human risk is not established), along with reported cases of pancreatitis, gallbladder disease and gallstones, kidney injury from dehydration, and, with tirzepatide, possible reduced absorption of oral contraceptives. Rapid weight loss can also cause loss of muscle mass, which the WW GLP-1 Success Program tries to counter with high-protein and strength guidance. Seek prompt medical attention for severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction, and report concerning symptoms to your care team. This is not a complete list of side effects.
Starts at $99/mo from Sequence (WeightWatchers).
As of 2026, WW Clinic / Med+ membership is commonly advertised at about $25/month for the first two to three months, then roughly $74/month for the remainder of a 12-month plan, with month-to-month options reported around $149/month. Membership covers clinician visits, insurance coordination, labs, coaching, and the WW app, but the medication is billed separately. List prices for brand-name GLP-1s can run roughly $1,000 to $1,350 per month, but few people pay that: WeightWatchers and the manufacturers offer cash-pay programs that are far lower (for example, Novo Nordisk's self-pay Wegovy oral tablet has been offered near $149/month and WW has advertised cash-pay injectable starter pricing well under list), and commercial insurance, where it covers weight-loss GLP-1s, can drop out-of-pocket costs to roughly $25 to $150/month. Coverage and savings eligibility vary widely, so verify your specific plan and compare WW's drug pricing against pharmacy and manufacturer options before committing.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If you qualify medically and want a structured program rather than a bare prescription, WW Clinic / Med+ is a solid, reasonably transparent choice with genuine clinical oversight and the WeightWatchers behavioral system behind it. Just budget for the medication separately, push hard on insurance coordination, compare WW's cash-pay drug pricing against pharmacy and manufacturer options, and understand you can lose access to the drug the moment you stop paying or your coverage lapses. Decisions about starting, changing, or stopping any medication should be made with your prescribing clinician.
Yes. WeightWatchers acquired the telehealth company Sequence in 2023 in a deal valued at about $132 million and rebranded it as WW Clinic, now offered through the Med+ membership. It is the same GLP-1 prescribing service operating under the WeightWatchers name.
Membership is commonly about $25/month for the first two to three months, then roughly $74/month for the rest of a 12-month plan, with month-to-month options around $149/month. The medication is billed separately. Brand-name GLP-1s can list around $1,000 to $1,350/month, but cash-pay programs from WeightWatchers and the manufacturers, and insurance where it applies, are often far cheaper.
Clinicians can prescribe FDA-approved GLP-1 medications including semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda), an oral semaglutide option, and non-GLP-1 drugs such as metformin or naltrexone/bupropion when appropriate. The clinician decides what is suitable based on your health history; not everyone is eligible.
Sometimes. WW Clinic coordinates with your insurer and handles prior authorizations, but coverage for GLP-1 drugs used for weight loss is inconsistent and often denied. If your plan covers the drug, out-of-pocket cost can fall to roughly $25 to $150/month; if not, you may pay a cash-pay price, which WeightWatchers and the manufacturers often set well below list. Verify your specific plan before committing.
A 2024 study in the journal Obesity (Ard et al.) of the WeightWatchers/Sequence platform found about 19.4% average body-weight loss at 12 months among patients with complete data, with roughly 21.2% on tirzepatide and the semaglutide formulations in the mid-teens. Because only a minority of patients had complete 12-month data, these are completer averages and likely overstate typical results. Individual outcomes vary and depend on staying on treatment and engaging with the program.
GLP-1 medications should be avoided if you have a personal or family history of medullary thyroid cancer (MTC) or MEN2 syndrome, are pregnant or planning pregnancy, or have had a serious allergic reaction to the drug. People with a history of pancreatitis, gallbladder disease, gastroparesis, or significant kidney problems need careful clinician evaluation. A licensed clinician makes the final decision based on your full history.
The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst when starting or increasing the dose and often improving over time. Less common but serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and a boxed warning for thyroid C-cell tumors based on animal data. Muscle loss during rapid weight loss is also a concern. This is not a complete list; report severe or persistent symptoms to your care team.
Weight regain is common after stopping GLP-1 medications because appetite tends to return toward baseline. Access to the prescription also ends if you cancel your WW membership or lose insurance coverage. For many people these drugs are used as a long-term treatment rather than a short course, but any decision to stop should be made with your clinician.
It is a legitimate US telehealth service that uses board-certified clinicians to prescribe FDA-approved medications and has published real-world outcome data. As with any GLP-1 program, the main concerns are cost transparency around the separately billed medication, the inherent side effects of these drugs, and the limits of fully remote care, rather than the platform's legitimacy. Safety depends on appropriate clinical screening and monitoring.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Sequence by WeightWatchers — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
Same-category options, scored on the same six-axis rubric. Higher is better.